相关实验视频

Updated: May 2, 2026

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation

Published on: January 29, 2019

在治疗MPO-ANCA相关血管炎后的Rituximab治疗后,晚发性中性

Kentaro Watanabe¹, Noriaki Shimada¹, Motoko Kanzaki¹

¹Department of Nephrology, Kurashiki Central Hospital, Japan.

Internal medicine (Tokyo, Japan)

|July 17, 2024

概括

晚发性中性 (R-LON) 是Rituximab的一个未被认可的副作用. 这一案例突出显示R-LON在患有功能衰竭的老年患者中引起严重感染,强调需要保持警.

科学领域:

免疫学免疫学免疫学
血液学血液学血液学
腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

利图西马布是一种用于自身免疫性疾病的单克隆抗体.
晚发性中性 (R-LON) 是Rituximab的一种潜在的副作用.
R-LON通常会自发消失,但可能导致严重的并发症.

研究的目的:

报告由于R-LON.LON引起的严重发烧性中性质的病例.
突出R-LON在患有功能衰竭的老年患者中的风险.
强调在治疗rituximab后对R-LON的监测的重要性.

主要方法:

一个91岁的女性患者的病例报告,患有骨髓氧化酶抗中性细胞质抗体相关的血管炎.
患者接受了利图西马布治疗血管炎.
治疗后对不良事件的监测,包括治疗后的中性质减退症.

主要成果:

患者在最后一次Rituximab剂量服用54天后出现发烧性中性.
这种情况被诊断为R-LON.
用花细胞殖民地刺激因子和抗生素治疗导致改善.

结论:

在Rituximab治疗后,晚发性中性可能导致严重的感染.
老年患者和功能衰竭患者的风险增加.
即使在停止服用Rituximab后,对R-LON的警监测至关重要.

关键词:

与MPO-ANCA相关的血管炎年长的老人老年人老年人.晚期发病的中性质减退症.功能衰竭功能衰竭这就是Rituximab.

更多相关视频

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

Published on: May 12, 2023

相关概念视频

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...